Table 1

Clinical characteristics, cardiovascular risk factors and cardiovascular risk scores of 112 biologically-naïve Rheumatoid Arthritis patients at baseline and after 3 months and 6 months of follow-up

VariablesBaseline3rd month6th month
CDAI18.3 (12.7)8 (7.8)***5.9 (4.2)***
mHAQ-DI0.9 (0.8)0.7 (0.8)***0.6 (0.7)***
Glucocorticoids dose mg/dl4.3 (3.4)3.5 (2.5)**2.9 (2.4)***
Glucocorticoids, n (%)79 (70.5)72 (64.3)67 (59.8)**
csDMARDs, n (%)97 (86.5)94 (83.9)91 (81.3)
Systolic blood pressure mm Hg126.7 (16.8)124.3 (17.3)124.9 (18.2)
Diastolic blood pressure mm Hg78.8 (9.4)77.6 (9.6)78.2 (10.7)
Total cholesterol mg/dl197.3 (38.2)205.8 (37.3)**201 (34.6)
HDL-cholesterol mg/dl60.1 (16.9)62.9 (15.9)61.8 (15.5)
Total cholestrol /HDL ratio3.4 (1.1)3.4 (0.9)3.4 (0.9)
Triglycerides mg/dl112.3 (78.2)111.1 (61.5)109.1 (53.7)
CRP mg/l12.8 (17.1)6.6 (10.5)***6.2 (8.5)***
BMI kg/m2 25.6 (5.4)26 (4.9)25.6 (4.9)
Diabetes, n (%)6 (5.4)7 (6.3)7 (6.3)
Hyperlipidaemia, n (%)45 (40.2)70 (62.5)***66 (58.9)**
Hypertension, n (%)31 (27.7)32 (28.6)32 (28.6)
Hypertension therapy, n (%)26 (23.2)29 (25.9)30 (26.8)
“Progetto Cuore” nr.1126.9 (11.3)6.7 (11.1)7 (11.9)
QRISK3-2018 nr.11210.8 (11.3)10.3 (10.8)10.4 (11.4)
RRS nr.1056.9 (8.8)6 (6.9)5.8 (6.9)**
ERS-RA nr.11210.8 (11.9)9.8 (10.9)**9.6 (10.5)***
  • Values are expressed as mean (SD) unless otherwise indicated.

  • Seven patients with diabetes were excluded in thecalculation of RRS as diabetes was an exclusion criteria.

  • *p<0.05; **p<0.01; ***p<0.001 vs baseline.

  • BMI, Body mass index; CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; ERS-RA, Expanded Risk Score inRheumatoid Arthritis; HDL, High-density lipoprotein; RRS, Reynolds risk score; csDMARDs, conventionalsynthetic disease modifying antirheumatic drugs; mHAQ-DI, modified Health Assessment Questionnaire Disability Index.